Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 504179, 9 pages
http://dx.doi.org/10.1155/2015/504179
Research Article

Prognostic Significance of Microvessel Density Determining by Endoglin in Stage II Rectal Carcinoma: A Retrospective Analysis

1Department of Surgery, Croatian Hospital “Dr. fra Mato Nikolic”, 72 276 Nova Bila, Bosnia and Herzegovina
2Department of Pathology, School of Medicine, University of Rijeka, 51 000 Rijeka, Croatia

Received 17 February 2015; Revised 24 April 2015; Accepted 4 May 2015

Academic Editor: Hans J. Schmoll

Copyright © 2015 Zeljko Martinovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar
  2. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012,” European Journal of Cancer, vol. 49, no. 6, pp. 1374–1403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. Cancer Registry Federation of Bosnia and Herzegovina, Overview of Malignantneoplasm, Public Health Institute of Federation of Bosnia and Herzegovina, 2011.
  4. E. Finlayson, “RAMPing up the quality of rectal cancer surgery,” Journal of Clinical Oncology, vol. 32, no. 27, pp. 2938–2939, 2014. View at Publisher · View at Google Scholar
  5. A. Vignali and P. de Nardi, “Multidisciplinary treatment of rectal cancer in 2014: where are we going?” World Journal of Gastroenterology, vol. 20, no. 32, pp. 11249–11261, 2014. View at Publisher · View at Google Scholar
  6. R. Glynne-Jones, “Do T3 rectal cancer always need radiochemotherapy?” in Early Gastrointestinal Cancers II: Rectal Cancer, vol. 203 of Recent Results in Cancer Research, pp. 95–115, Springer, Berlin, Germany, 2014. View at Publisher · View at Google Scholar
  7. N. I. Schneider and C. Langner, “Prognostic stratification of colorectal cancer patients: current perspectives,” Cancer Management and Research, vol. 6, no. 2, pp. 291–300, 2014. View at Publisher · View at Google Scholar
  8. S. F. Martins, R. M. Reis, A. M. Rodrigues, F. Baltazar, and A. L. Filho, “Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies,” World Journal of Clinical Oncology, vol. 2, no. 6, pp. 272–280, 2011. View at Google Scholar
  9. R. Oklu, T. G. Walker, S. Wicky, and R. Hesketh, “Angiogenesis and current antiangiogenic strategies for the treatment of cancer,” Journal of Vascular and Interventional Radiology, vol. 21, no. 12, pp. 1791–1805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Marioni, A. Staffieri, E. Manzato et al., “A higher CD105-assessed microvessel density and worse prognosis in elderly patients with laryngeal carcinoma,” Archives of Otolaryngology—Head & Neck Surgery, vol. 137, no. 2, pp. 175–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Des Guetz, B. Uzzan, P. Nicolas et al., “Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature,” British Journal of Cancer, vol. 94, no. 12, pp. 1823–1832, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Bellone, C. Gramigni, B. Vizio et al., “Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa,” International Journal of Oncology, vol. 37, no. 5, pp. 1153–1165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Fonsatti, H. J. M. Nicolay, M. Altomonte, A. Covre, and M. Maio, “Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours,” Cardiovascular Research, vol. 86, no. 1, pp. 12–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Bernabeu, J. M. Lopez-Novoa, and M. Quintanilla, “The emerging role of TGF-β superfamily coreceptors in cancer,” Biochimica et Biophysica Acta, vol. 1792, no. 10, pp. 954–973, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. “Colon and rectum,” in AJCC Cancer Staging Manual, B. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene, and A. Trotti, Eds., pp. 143–164, Springer, New York, NY, USA, 7th edition, 2010.
  16. V. Barresi, L. R. Bonetti, A. Ieni, G. Branca, L. Baron, and G. Tuccari, “Histologic grading based on counting poorly differentiated clusters in preoperative biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients,” Human Pathology, vol. 45, no. 2, pp. 268–275, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, “Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma,” The New England Journal of Medicine, vol. 324, no. 1, pp. 1–8, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Dassoulas, M. Gazouli, G. Theodoropoulos et al., “Vascular endothelial growth factor and endoglin expression in colorectal cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 5, pp. 703–708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Sǿreide, “Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research,” Journal of Clinical Pathology, vol. 62, no. 1, pp. 1–5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. C. Compton, “Optimal pathologic staging: defining stage II disease,” Clinical Cancer Research, vol. 13, no. 22, pp. 6862s–6870s, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Zhu, Y. Xu, W. Gu et al., “Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients,” Radiation Oncology, vol. 5, article 118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Nassiri, M. D. Cusimano, B. W. Scheithauer et al., “Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy,” Anticancer Research, vol. 31, no. 6, pp. 2283–2289, 2011. View at Google Scholar · View at Scopus
  23. S. Svagzdys, V. Lesauskaite, D. Pavalkis, I. Nedzelskiene, D. Pranys, and A. Tamelis, “Microvessel density as new prognostic marker after radiotherapy in rectal cancer,” BMC Cancer, vol. 9, no. 3, article 95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Skoufi, D. L. Arvanitis, L. Lampri et al., “Association of claudin-1 with E- cadherin/catenin complex, microvessel density (MVD)-related markers, and clinicopathological features in colorectal carcinoma,” Journal of Interdisciplinary Histopathology, vol. 2, no. 3, pp. 126–144, 2014. View at Publisher · View at Google Scholar
  25. L. J. A. C. Hawinkels, P. Kuiper, E. Wiercinska et al., “Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis,” Cancer Research, vol. 70, no. 10, pp. 4141–4150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. H. Fox, G. F. Whalen, M. M. Sanders et al., “Angiogenesis in normal tissue adjacent to colon cancer,” Journal of Surgical Oncology, vol. 69, no. 4, pp. 230–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. R. S. Saad, Y. L. Liu, G. Nathan, J. Celebrezze, D. Medich, and J. F. Silverman, “Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer,” Modern Pathology, vol. 17, no. 2, pp. 197–203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. D. Wagner, M. G. Fakih, and G. Y. Yang, “Management of stage II/III rectal cancer,” Journal of Gastrointestinal Oncology, vol. 1, no. 2, pp. 112–119, 2010. View at Google Scholar
  29. F. Prall, U. Gringmuth, H. Nizze, and M. Barten, “Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival,” Histopathology, vol. 42, no. 5, pp. 482–491, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Uribarrena A, J. Ortego, J. Fuentes, N. Raventós, P. Parra, and R. Uribarrena E, “Prognostic value of microvascular density in dukes A and B (T1–T4, N0, M0) colorectal carcinomas,” Gastroenterology Research and Practice, vol. 2009, Article ID 679830, 7 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Li, R. Gardy, B. K. Seon et al., “Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis,” British Journal of Cancer, vol. 88, no. 9, pp. 1424–1431, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. A. A. Romani, A. F. Borghetti, P. Del Rio, M. Sianesi, and P. Soliani, “The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count,” Journal of Surgical Oncology, vol. 93, no. 6, pp. 446–455, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Pérez-Gómez, G. Del Castillo, J. F. Santibáñez, J. M. López-Novoa, C. Bernabéu, and M. Quintanilla, “The role of the TGF-β coreceptor endoglin in cancer,” TheScientificWorldJOURNAL, vol. 10, pp. 2367–2384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. C. S. Craft, D. Romero, C. P. H. Vary, and R. C. Bergan, “Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway,” Oncogene, vol. 26, no. 51, pp. 7240–7250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Anderberg, S. I. Cunha, Z. Zhai et al., “Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination,” The Journal of Experimental Medicine, vol. 210, no. 3, pp. 563–579, 2013. View at Publisher · View at Google Scholar · View at Scopus